It was founded in 2005 and Key employees including CEO and directors have a cumulative experience in the biopharmaceutical field. BiocurePharm has already experiences to developed several recombinant biosimilars such as Interferon-β, Filgrastim, EPO, Ranibizumab, and Enbrel. Based on such achievements, BiocurePharm started to develop the immunocell therapy, CAR-T cell therapy, with Pharosvacine in 2016. And non-clinical study completed in 2018 and IND submitted for clinical study for relapse and refractory acute lymphoblastic leukemia.